Loading...
On May 16, the results of one of the largest U.S. government clinical trials on tuberculosis (TB) preventive therapy were reported in an oral presentation at the 2011 meeting of the American Thoracic Society. In this randomized study, 3 months of directly observed combination therapy (rifapentine 900 mg plus isoniazid 900 mg once weekly) was compared with the current standard regimen — 9 months of nonobserved monotherapy (isoniazid 300 mg daily) — in 8053 individuals with latent TB infection, predominantly in the U.S. and Canada. Participants were evaluated 33 months after enrollment. Because of concern about drug interactions, HIV-infected individuals taking antiretrovirals were excluded.
TB disease developed in 7 participants in the 3-mont…